CRBU

#3690
Caribou Biosciences, Inc. - Common Stock
1.5 7 USD
+0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
1.57
1.58
Intervallo Annuale
1.38
3.53
Variazione giornaliera
+1.29%
Variazione Mensile
+6.80%
Variazione di 6 mesi
-12.29%
Variazione Annuale
-16.49%
Chiusura Precedente
1.5 5
Open
1.5 8
Minimo
1.5 7
Massimo
1.5 8
Volume
61
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Caribou Biosciences, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Caribou Biosciences, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Caribou Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Caribou Biosciences, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Caribou Biosciences, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Caribou Biosciences, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Caribou Biosciences, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Caribou Biosciences, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Caribou Biosciences, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Caribou Biosciences, Inc. current report, Q4 FY2025
8-K

Caribou Biosciences, Inc. current report, Q2 FY2024

Full document

Caribou Biosciences, Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K Current Report, dated June 13, 2024, covers the results of Caribou Biosciences, Inc.'s Annual Meeting of Stockholders held on that date. The company is incorporated in Delaware and trades on the NASDAQ Global Select Market under the symbol CRBU.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.

Material Changes and Voting Results

The following proposals were submitted to and voted upon by stockholders:

  • Proposal 1: Election of Three Class III Directors
    • Rachel Haurwitz, Ph.D.: Elected with 57,375,324 votes for, 2,287,189 withheld, and 13,621,407 broker non-votes.
    • Dara Richardson-Heron, M.D.: Elected with 50,232,080 votes for, 9,430,433 withheld, and 13,621,407 broker non-votes.
    • Natalie Sacks, M.D.: Elected with 50,173,915 votes for, 9,488,598 withheld, and 13,621,407 broker non-votes.
  • Proposal 2: Ratification of Independent Registered Public Accounting Firm
    • Stockholders ratified the selection of Deloitte & Touche LLP for the fiscal year ending December 31, 2024.
    • Votes For: 73,021,434
    • Votes Against: 231,293
    • Votes Abstain: 31,193

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the definitive proxy statement on Schedule 14A filed on April 25, 2024.

Key Facts for Investor Verification

  • Verify the total number of shares outstanding to calculate the percentage of votes for each director nominee.
  • Review the Schedule 14A proxy statement filed on April 25, 2024, for detailed biographies of the elected directors and the rationale for the auditor selection.
  • Confirm the company's current financial status and cash runway through the most recent 10-Q or 10-K filing, as this 8-K contains no financial data.

Notizie